Zhiming Li

Dr. Zhiming Li


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZLZhiming Li
Zhiming Li
MNMing Ni
Ming Ni
HYHaiyang Yu
Haiyang Yu
LWLili Wang
Lili Wang
XZXiaoming Zhou
Xiaoming Zhou
YGYuanxiang Gao
Yuanxiang Gao
Purpose. To investigate the relationship between gut microbiota and liver fibrosis and establish a microbiota biomarker for detecting and staging liver fibrosis. Methods. 131 Wistar rats were used in our study, and liver fibrosis was induced by carbon tetrachloride. Stool samples were collected within 72 hours after the last administration. The V4 regions of 16S rRNA gene were amplified. The sequencing data was processed using the Quantitative Insights Into Microbial Ecology (QIIME version 1.9). The diversity, principal coordinate analysis (PCoA), nonmetric multidimensional scaling (NMDS), and linear discriminant analysis (LDA) effect size (LEfSe) were performed. Random‐Forest classification was performed for discriminating the samples from different groups. Microbial function was assessed using the PICRUST. Results. The Simpson in the control group was lower than that in the liver fibrosis group (p = 0.048) and differed significantly among different fibrosis stages (p = 0.047). The Chao1 index in the control group was higher than that in the liver fibrosis group (p < 0.001). NMDS analysis showed a marked difference between the control and liver fibrosis groups (p < 0.001). PCoA analysis indicated the different community composition between the control and liver fibrosis groups with variances of PC1 13.76% and PC2 5.89% and between different liver fibrosis stages with variances of PC1 10.51% and PC2 7.78%. LEfSe analysis showed alteration of gut microbiota in the liver fibrosis group. Biomarkers obtained from Random‐Forest classification showed excellent diagnostic accuracy in prediction of liver fibrosis with AUROCs of 0.99. The AUROCs were 0.77~0.84 in prediction of stage F4. There were six increased and 17 decreased metabolic functions in the liver fibrosis group and 6 metabolic functions significantly differed among four liver fibrosis stages. Conclusion. Gut microbiota is a potential biomarker for detecting and staging liver fibrosis with high diagnostic accuracies.

9 November 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MNMing Ni
Ming Ni
XZXiaoming Zhou
Xiaoming Zhou
JLJingwei Liu
Jingwei Liu
HYHaiyang Yu
Haiyang Yu
YGYuanxiang Gao
Yuanxiang Gao
ZLZhiming Li
Zhiming Li
Background: The clinicopathological classification of breast cancer is proposed according to therapeutic purposes. It is simplified and can be conducted easily in clinical practice, and this subtyping undoubtedly contributes to the treatment selection of breast cancer. This study aims to investigate the feasibility of using a Fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI for predicting the clinicopathological subtypes of breast cancer.Methods: Patients who underwent breast magnetic resonance imaging were confirmed by retrieving data from our institutional picture archiving and communication system (PACS) between March 2013 and September 2017. Five clinicopathological subtypes were determined based on the status of ER, PR, HER2 and Ki-67 from the immunohistochemical test. The radiomic features of diffusion-weighted imaging were derived from the volume of interest (VOI) of each tumour. Fisher discriminant analysis was performed for clinicopathological subtyping by using a backward selection method. To evaluate the diagnostic performance of the radiomic features, ROC analyses were performed to differentiate between immunohistochemical biomarker-positive and -negative groups.Results: A total of 84 radiomic features of four statistical methods were included after preprocessing. The overall accuracy for predicting the clinicopathological subtypes was 96.4% by Fisher discriminant analysis, and the weighted accuracy was 96.6%. For predicting diverse clinicopathological subtypes, the prediction accuracies ranged from 92 to 100%. According to the cross-validation, the overall accuracy of the model was 82.1%, and the accuracies of the model for predicting the luminal A, luminal BHER2-, luminal BHER2+, HER2 positive and triple negative subtypes were 79, 77, 88, 92 and 73%, respectively. According to the ROC analysis, the radiomic features had excellent performance in differentiating between different statuses of ER, PR, HER2 and Ki-67.Conclusions: The Fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI is a reliable method for the prediction of clinicopathological breast cancer subtypes.

12 October 2020 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
MNMing Ni
Ming Ni
LWLili Wang
Lili Wang
HYHaiyang Yu
Haiyang Yu
XWXiaoyi Wen
Xiaoyi Wen
YYYinghua Yang
Yinghua Yang
ZLZhiming Li
Zhiming Li

21 December 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
HZHaichen Zhao
Haichen Zhao
XZXiaoya Zhang
Xiaoya Zhang
BHBaoxiang Huang
Baoxiang Huang
XSXiaojuan Shi
Xiaojuan Shi
LXLongyang Xiao
Longyang Xiao
ZLZhiming Li
Zhiming Li

14 January 2024 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
LXLongyang Xiao
Longyang Xiao
HZHaichen Zhao
Haichen Zhao
SLShunli Liu
Shunli Liu
WDWenlu Dong
Wenlu Dong
YGYuanxiang Gao
Yuanxiang Gao
ZLZhiming Li
Zhiming Li

27 July 2024 in Heliyon
Verified
Journal Article
Open access
HZHaichen Zhao
Haichen Zhao
XZXiaoya Zhang
Xiaoya Zhang
YGYuanxiang Gao
Yuanxiang Gao
LWLili Wang
Lili Wang
LXLongyang Xiao
Longyang Xiao
ZLZhiming Li
Zhiming Li
Previous studies had confirmed that some deep learning models had high diagnostic performance in staging liver fibrosis. However, training efficiency of models predicting liver fibrosis need to be improved to achieve rapid diagnosis and precision medicine. The deep learning framework of EfficientNetV2-S was noted because of its faster training speed and better parameter efficiency compared with other models. Our study sought to develop noninvasive predictive models based on EfficientNetV2-S framework for staging liver fibrosis. Patients with chronic liver disease who underwent multi-parametric abdominal MRI were included in the retrospective study. Data augmentation methods including horizontal flip, vertical flip, perspective transformation and edge enhancement were applied to multi-parametric MR images to solve the data imbalance between different liver fibrosis groups. The EfficientNetV2-S models were used for the prediction of liver fibrosis stages F1-2, F1-3, F3, F4 and F3-4. We evaluated the diagnostic performance of our models in training, validation, and test sets by using receiver operating characteristic curve (ROC) analysis. The total training time of EfficientNetV2-S was about 6 h. For differentiating of F1-2 vs F3, the accuracy, sensitivity and specificity of EfficientNetV2-S model were 96.2 %, 96.4 % and 96.0 % in the test set. The AUC in test set was 0.559. The accuracy, sensitivity and specificity were 82.1 %, 74.5 % and 89.6 % in the test set by using EfficientNetV2-S model to differentiate F1-2 vs F3-4, and the AUC in test set were 0.763. For differentiating F1-3 vs F4, the accuracy, sensitivity and specificity of EfficientNetV2-S model were 71.5 %, 73.4 % and 69.5 % in the test set. The AUC was 0.553 in test set. For differentiating F1-2 vs F4, the accuracy, sensitivity and specificity of our model were 84.3 %, 80.2 % and 88.3 % in the test set, and the AUC was 0.715, respectively. For differentiating F3 vs F4, the accuracy, sensitivity and specificity of EfficientNetV2-S model were 92.5 %, 89.1 % and 95.6 % in the test set, and the AUC was 0.696 in the test set. The EfficientNetV2-S models based on multi-parametric MRI had the feasibility for staging of liver fibrosis because they showed high training speed and diagnostic performance in our study.